Aptevo Therapeutics

Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology

placeSeattle, Washington, United States calendar_todayFounded 2016 groups45 employees language aptevotherapeutics.com

Registered entities

Social engagement

Social engagement: 4.4K social following, 5 posts in the last 12 months — above the industry median.

Investor mix

3 investors on record.

Investor typeCountShare
Private equity133%
Bank & private debt133%
Other / undisclosed133%

Recent activity

2 Jun 2026
Leadership hire
SVP & Chief Scientific Officer
22 Apr 2026
Event
Life Science Innovation Northwest
Coming soon